OneSource Specialty Pharma Ltd
Wed 27/05/2026,15:56:20 | NSE : ONESOURCE
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1821.90
Previous Close
₹ 1805.60
Volume
155030
Mkt Cap ( Rs. Cr)
₹20534.21
High
₹ 1821.90
Low
₹ 1760.40
52 Week High
₹ 2248.00
52 Week Low
₹ 1057.00
Book Value Per Share
₹ 507.28
Dividend Yield
0.00
Face Value
₹ 1.00
What’s Your Call?
Collective community sentiment on OneSource Specialty Pharma Ltd
Your Vote -
Buy
66.67%
Hold
0.00%
Sell
33.33%
66.67%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
1791.10
199
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
199
Option Chain
Analyzes market sentiment, predicts OneSource Specialty Pharma Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
OneSource Specialty - Updates
-
OneSource Specialty - Updates
-
OneSource Specialty - General- Update
-
OneSource Specialty - Updates
-
OneSource Specialty - General-Update
-
OneSource Specialty - Copy of Newspaper Publication
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates
-
OneSource Specialty - Press Release
-
OneSource Specialty - Investor Presentation
-
OneSource Specialty - General Updates
-
OneSource Specialty - Change in Auditors
-
OneSource Specialty - General Updates
-
OneSource Specialty - Resignation
-
OneSource Specialty - Outcome of Board Meeting
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Investor Presentation
-
OneSource Specialty - Update On Composite Scheme Of Amalgamation
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
OneSource Specialty Q4 net profit down 87.67% at Rs 21.48 cr
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Change in Management
-
OneSource Specialty - Board Meeting Outcome for Intimation Of The Outcome Of The Board Meeting Dated May 13, 2026 For Approva
-
OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
OneSource Specialty - Board Meeting Intimation for Intimation Regarding Board Meeting Under Regulation 29 Of SEBI (Listing O
-
OneSource Specialty - Press Release
-
OneSource Specialty Pharma backs second generic semaglutide approval in Canada
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
OneSource Specialty - Press Release
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
OneSource Specialty - General Updates
-
OneSource Specialty - General-Update
-
OneSource Specialty - Press Release
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
OneSource Specialty has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
OneSource Specialty - Updates
-
OneSource Specialty - Intimation Of \Renewal Of EU -GMP Certification For Onesource : Flagship Unit II Facility
-
OneSource Specialty - Updates
-
OneSource Specialty - Intimation Of ESG Rating
-
OneSource Specialty - General Updates
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
-
OneSource Specialty - Trading Window
-
OneSource Specialty - Update On Composite Scheme Of Arrangement
-
OneSource Specialty - General Updates
-
OneSource Specialty - Credit Rating- Others
-
OneSource Specialty - Analysts/Institutional Investor Meet/Con. Call Updates
-
OneSource Specialty - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
OneSource collaborates with Xbrane Biopharma AB
Key fundamentals
Evaluate the intrinsic value of OneSource Specialty Pharma Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | |
|---|---|---|---|---|---|
| Assets | 7226.518 | 6691.688 | 957.877 | 1622.144 | |
| Liabilities | 7226.518 | 6691.688 | 957.877 | 1622.144 | |
| Equity | 11.462 | 11.443 | 4.01 | 4.01 | |
| Gross Profit | 268.993 | 369.275 | -88.239 | -160.687 | |
| Net Profit | 21.21 | 19.31 | -391.165 | -799.83 | |
| Cash From Operating Activities | 55.175 | -47.283 | -107.211 | -162.88 | |
| NPM(%) | 1.5 | 1.48 | -227.52 | -2065.99 | |
| Revenue | 1405.381 | 1299.589 | 171.919 | 38.714 | |
| Expenses | 1136.388 | 930.314 | 260.158 | 199.401 | |
| ROE(%) | 0.36 | 0.33 | -6.72 | -13.75 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to OneSource Specialty Pharma Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 716.10 | 0.23 | 0.00 | 1023.22 | -26.19 | 0.70 |
| Lotus Eye Hospital and Institute Ltd | 108.30 | -1.02 | 3610.00 | 3728.46 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.14 | 1.28 | 0.00 | 23389.90 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 761.25 | 1.91 | 0.00 | 3516.03 | -363.15 | 0.00 |
Company Info
Our Company was incorporated as a private limited company under the Companies Act, 1956, with the name and style of `Inbiopro Solutions Private Limited' and a certificate of incorporation dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The name of our Company was then changed to `Stelis Biopharma Private Limited', pursuant to a scheme of amalgamation and a certificate of incorporation pursuant to change of name dated December 24, 2014, was issued by the Registrar of Companies, Karnataka at Bangalore. Our Company was then converted from a private limited company to a public company on July 31, 2021, and consequently renamed as `Stelis Biopharma Limited' and a fresh certificate of incorporation dated July 31, 2021, was issued by the Registrar of Companies, Karnataka at Bangalore. Subsequently, the name of our Company was changed to its present name `Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.Major Events and Milestones:2007- Our Company was incorporated under the name and style of `Inbiopro Solutions Private Limited'2014- The name of our Company was changed to `Stelis Biopharma Private Limited'2021- Our Company was converted from a private limited company to a public limited company and consequently renamed as `Stelis Biopharma Limited'2024- The name of our Company was changed to `Onesource Specialty Pharma Limited'- Demerger, transfer and vesting of the Demerged Undertaking from Strides and Steriscience into our Company on a going concern basis pursuant to the Scheme of Arrangement2025-OneSource Specialty Pharma Limited and Sweden-based biotechnology firm Xbrane Biopharma AB (listed on Nasdaq under the ticker XBRANE), have announced a strategic partnership for the commercial manufacturing of Xbrane’s biosimilar portfolio for global markets.-OneSource Specialty Pharma Limited has received a "Voluntary Action Indicated" (VAI) classification from the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.
Our Company was incorporated as a private limited company under the Companies Act, 1956, with the name and style of `Inbiopro Solutions Private Limited' and a certificate of incorporation dated June 12, 2007, was issued by the Registrar of Companies, Karnataka at Bangalore. The name of our Company was then changed to `Stelis Biopharma Private Limited', pursuant to a scheme of amalgamation and a certificate of incorporation pursuant to change of name dated December 24, 2014, was issued by the Registrar of Companies, Karnataka at Bangalore. Our Company was then converted from a private limited company to a public company on July 31, 2021, and consequently renamed as `Stelis Biopharma Limited' and a fresh certificate of incorporation dated July 31, 2021, was issued by the Registrar of Companies, Karnataka at Bangalore. Subsequently, the name of our Company was changed to its present name `Onesource Specialty Pharma Limited' on February 13, 2024, and a fresh certificate of Incorporation dated February 13, 2024, was issued by the Registrar of Companies, Karnataka at Bangalore.Major Events and Milestones:2007- Our Company was incorporated under the name and style of `Inbiopro Solutions Private Limited'2014- The name of our Company was changed to `Stelis Biopharma Private Limited'2021- Our Company was converted from a private limited company to a public limited company and consequently renamed as `Stelis Biopharma Limited'2024- The name of our Company was changed to `Onesource Specialty Pharma Limited'- Demerger, transfer and vesting of the Demerged Undertaking from Strides and Steriscience into our Company on a going concern basis pursuant to the Scheme of Arrangement2025-OneSource Specialty Pharma Limited and Sweden-based biotechnology firm Xbrane Biopharma AB (listed on Nasdaq under the ticker XBRANE), have announced a strategic partnership for the commercial manufacturing of Xbrane’s biosimilar portfolio for global markets.-OneSource Specialty Pharma Limited has received a "Voluntary Action Indicated" (VAI) classification from the U.S. Food and Drug Administration (USFDA), confirming its continued compliance.
Read More
Parent Organisation
OneSource Specialty Pharma Ltd.
Founded
12/06/2007
Managing Director
Mr.Neeraj Sharma
NSE Symbol
ONESOURCEEQ
FAQ
The current price of OneSource Specialty Pharma Ltd is ₹ 1791.10.
The 52-week high for OneSource Specialty Pharma Ltd is ₹ 1821.90 and the 52-week low is ₹ 1760.40.
The market capitalization of OneSource Specialty Pharma Ltd is currently ₹ 20534.21. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy OneSource Specialty Pharma Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in OneSource Specialty Pharma Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase OneSource Specialty Pharma Ltd shares.
The CEO of OneSource Specialty Pharma Ltd is Mr.Neeraj Sharma, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
